Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma

A Gynecologic Oncology Group study

Charles Kunos, Shamshad Ali, Fadi W. Abdul-Karim, Frederick Stehman, Steven Waggoner

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: The objective of the study was to study posttherapy chemoradiation hysterectomy histology with long-term survival in bulky stage 1B cervical cancer patients. Study Design: Gynecologic Oncology Group protocols 71 and 123 enrolled 464 patients randomly allocated to pelvic radiation (75 Gy, n = 291) plus hysterectomy (RTH) or to pelvic radiation (75 Gy) and cisplatin (40 mg/m2, n = 176) plus hysterectomy (RTCH). Risk of progression and death were evaluated by posttherapy hysterectomy response (good: <10% viable; poor: ≥10% viable). Results: Median survivor follow-up was 112 months. Relative risks of disease progression and death were 0.656 (95% confidence interval, 0.4720.912) and 0.638 (95% confidence interval, 0.449-0.908), favoring RTCH. Good response patients (345; 74%) had similar 10 year overall survival (OS) and progression-free survival (PFS) after RTH or RTCH (P > .47). Poor response patients after RTCH had superior OS (P = .046) and PFS (P = .084). Extrapelvic recurrences occurred more often in poor response patients. Conclusion: Posttherapy viable residual disease less than 10% was associated with reduced risk of progression and cancer-related death.

Original languageEnglish
JournalAmerican Journal of Obstetrics and Gynecology
Volume203
Issue number4
DOIs
StatePublished - Oct 2010

Fingerprint

Hysterectomy
Carcinoma
Radiation Dosage
Survival
Uterine Cervical Neoplasms
Cisplatin
Histology
Recurrence
Neoplasms

Keywords

  • cervix cancer
  • chemoradiation
  • hysterectomy histopathology

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma : A Gynecologic Oncology Group study. / Kunos, Charles; Ali, Shamshad; Abdul-Karim, Fadi W.; Stehman, Frederick; Waggoner, Steven.

In: American Journal of Obstetrics and Gynecology, Vol. 203, No. 4, 10.2010.

Research output: Contribution to journalArticle

@article{30d4b933167f4663b28973493d41ba1a,
title = "Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: A Gynecologic Oncology Group study",
abstract = "Objective: The objective of the study was to study posttherapy chemoradiation hysterectomy histology with long-term survival in bulky stage 1B cervical cancer patients. Study Design: Gynecologic Oncology Group protocols 71 and 123 enrolled 464 patients randomly allocated to pelvic radiation (75 Gy, n = 291) plus hysterectomy (RTH) or to pelvic radiation (75 Gy) and cisplatin (40 mg/m2, n = 176) plus hysterectomy (RTCH). Risk of progression and death were evaluated by posttherapy hysterectomy response (good: <10{\%} viable; poor: ≥10{\%} viable). Results: Median survivor follow-up was 112 months. Relative risks of disease progression and death were 0.656 (95{\%} confidence interval, 0.4720.912) and 0.638 (95{\%} confidence interval, 0.449-0.908), favoring RTCH. Good response patients (345; 74{\%}) had similar 10 year overall survival (OS) and progression-free survival (PFS) after RTH or RTCH (P > .47). Poor response patients after RTCH had superior OS (P = .046) and PFS (P = .084). Extrapelvic recurrences occurred more often in poor response patients. Conclusion: Posttherapy viable residual disease less than 10{\%} was associated with reduced risk of progression and cancer-related death.",
keywords = "cervix cancer, chemoradiation, hysterectomy histopathology",
author = "Charles Kunos and Shamshad Ali and Abdul-Karim, {Fadi W.} and Frederick Stehman and Steven Waggoner",
year = "2010",
month = "10",
doi = "10.1016/j.ajog.2010.05.005",
language = "English",
volume = "203",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma

T2 - A Gynecologic Oncology Group study

AU - Kunos, Charles

AU - Ali, Shamshad

AU - Abdul-Karim, Fadi W.

AU - Stehman, Frederick

AU - Waggoner, Steven

PY - 2010/10

Y1 - 2010/10

N2 - Objective: The objective of the study was to study posttherapy chemoradiation hysterectomy histology with long-term survival in bulky stage 1B cervical cancer patients. Study Design: Gynecologic Oncology Group protocols 71 and 123 enrolled 464 patients randomly allocated to pelvic radiation (75 Gy, n = 291) plus hysterectomy (RTH) or to pelvic radiation (75 Gy) and cisplatin (40 mg/m2, n = 176) plus hysterectomy (RTCH). Risk of progression and death were evaluated by posttherapy hysterectomy response (good: <10% viable; poor: ≥10% viable). Results: Median survivor follow-up was 112 months. Relative risks of disease progression and death were 0.656 (95% confidence interval, 0.4720.912) and 0.638 (95% confidence interval, 0.449-0.908), favoring RTCH. Good response patients (345; 74%) had similar 10 year overall survival (OS) and progression-free survival (PFS) after RTH or RTCH (P > .47). Poor response patients after RTCH had superior OS (P = .046) and PFS (P = .084). Extrapelvic recurrences occurred more often in poor response patients. Conclusion: Posttherapy viable residual disease less than 10% was associated with reduced risk of progression and cancer-related death.

AB - Objective: The objective of the study was to study posttherapy chemoradiation hysterectomy histology with long-term survival in bulky stage 1B cervical cancer patients. Study Design: Gynecologic Oncology Group protocols 71 and 123 enrolled 464 patients randomly allocated to pelvic radiation (75 Gy, n = 291) plus hysterectomy (RTH) or to pelvic radiation (75 Gy) and cisplatin (40 mg/m2, n = 176) plus hysterectomy (RTCH). Risk of progression and death were evaluated by posttherapy hysterectomy response (good: <10% viable; poor: ≥10% viable). Results: Median survivor follow-up was 112 months. Relative risks of disease progression and death were 0.656 (95% confidence interval, 0.4720.912) and 0.638 (95% confidence interval, 0.449-0.908), favoring RTCH. Good response patients (345; 74%) had similar 10 year overall survival (OS) and progression-free survival (PFS) after RTH or RTCH (P > .47). Poor response patients after RTCH had superior OS (P = .046) and PFS (P = .084). Extrapelvic recurrences occurred more often in poor response patients. Conclusion: Posttherapy viable residual disease less than 10% was associated with reduced risk of progression and cancer-related death.

KW - cervix cancer

KW - chemoradiation

KW - hysterectomy histopathology

UR - http://www.scopus.com/inward/record.url?scp=77957334056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957334056&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2010.05.005

DO - 10.1016/j.ajog.2010.05.005

M3 - Article

VL - 203

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 4

ER -